Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Regeneron Pharmaceuticals is launching a Phase 3 trial titled “A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma.” The goal is to see if Regeneron’s drug linvoseltamab can delay progression from high-risk smoldering multiple myeloma (HR-SMM) to active myeloma better than current standard therapy, an important step in moving treatment earlier in the disease and potentially expanding Regeneron’s oncology footprint.
Intervention/Treatment: The study compares two antibody drugs. Linvoseltamab (also known as REGN5458 or Lynozyfic™) is an experimental therapy designed to target early-stage disease and slow or prevent progression. Daratumumab (Darzalex® / Darzalex Faspro®), a well-established multiple myeloma drug, serves as the active comparator. The trial will track how well each option delays disease progression, as well as safety and how the body processes the drugs.
Study Design: This is an interventional Phase 3 study with randomized assignment, meaning participants are randomly placed in either the linvoseltamab or daratumumab group. The model is “parallel,” so each group receives only its assigned treatment throughout the study. The trial is open-label, so both doctors and patients know which drug is being given. The main goal is treatment-focused: to see which drug does a better job at delaying the move from high-risk smoldering disease to active multiple myeloma while keeping side effects manageable.
Study Timeline: The trial status is “Not yet recruiting,” with the first submission to the registry dated January 29, 2026, marking the formal start of set-up and regulatory documentation. No results have been submitted yet, which is expected at this early stage. The most recent update to the record was on February 5, 2026, showing that the protocol and key details have been recently reviewed and confirmed as the study moves toward site activation and patient enrollment.
Market Implications: For investors, this trial signals Regeneron’s push deeper into hematology and earlier-stage cancer treatment, which could add a new long-term revenue stream if linvoseltamab shows an edge over daratumumab. Success in high-risk smoldering multiple myeloma would position Regeneron against entrenched myeloma players such as Johnson & Johnson (daratumumab) and other large-cap oncology names, potentially lifting sentiment around Regeneron’s pipeline value. Near term, the update is more about pipeline optionality than earnings impact, but it supports a constructive view on REGN’s diversification beyond ophthalmology and immunology. Competitive risk remains high, yet a positive Phase 3 readout could meaningfully re-rate the stock by validating a new high-value indication in a market that rewards earlier intervention and durable responses.
The study is actively moving toward recruitment and remains ongoing in its setup phase, with more details and future updates available on the ClinicalTrials.gov portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
